原发性弥漫性大细胞性肠非霍奇金淋巴瘤的临床及生存分析

目的：对28例成人原发性弥漫性大细胞性（DLCL）肠非霍奇金淋巴瘤（NHL）的临床特点、治疗及生存情况进行总结。方法：采用回顾性分析研究。结果：79％的患者接受外科手术联合化疗，50％的患者取得CR，14％为PR，36％为NR－PD，中位随访时间62月，7例（25％）患者仍存活，3例（11％）患者带瘤生存，其余18例（64％）患者死亡。结论：本回顾性了分析28例原发性DLCL肠NHL的临床特征、治疗效果和生存情况，外科手术联合化疗为最常见的治疗方式，不同治疗策略，尤其是外科手术在治疗中的作用尚需前瞻性的随机研究进一步验证。

Clinical and Survival Analysis of Primary Intestinal Diffuse Large B-Cell Non-Hodgkin''''s Lymphoma

Objective To investigate the clinical features, treatment and survival rate of primary intestinal diffuse large B-cell(DLCL) non-Hodgkin's lymphoma (NHL).Methods 28 cases of intestinal NHL having DLCL histology were retrospectively reviewed and analyzed. Results 79% patients were treated by surgery-chemotherapy.50% attained complete remission (CR),14% attained partial remission (PR), 36% were no response-progressive disease (NR-PD).Over a median followed-up for 62 months in all 28 patients, 7 (25%) were alive and disease free, 3 (11%) were alive with loading tomor, and the remaining 18 (64%) were dead.Conclusion This series clinical features, treatment and outcome of NHL patients with primary intestinal DLCL was reviewed. Surgery-chemotherapy is the common treatment, prospective randomized studies can ascertain the precise role of surgical resection in primary intestinal NHL.